<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019344</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065779</org_study_id>
    <secondary_id>NCI-97-C-0171C</secondary_id>
    <secondary_id>NCI-T97-0064</secondary_id>
    <nct_id>NCT00019344</nct_id>
    <nct_alias>NCT00001585</nct_alias>
  </id_info>
  <brief_title>Flavopiridol in Treating Patients With Refractory Cancer</brief_title>
  <official_title>A Phase I Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Refractory Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase I trial to study the effectiveness of flavopiridol in treating patients who
      have refractory cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the dose-limiting toxicity and maximum tolerated dose of
      flavopiridol in patients with refractory solid tumors or lymphoma. 2. Determine the
      pharmacokinetics of this drug in these patients.

      OUTLINE: This is a dose-escalation study. Patients receive flavopiridol IV over 1 hour on day
      1. Treatment continues every 3 weeks in the absence of disease progression. A cohort of 3-6
      patients receives treatment at each dose level of flavopiridol. If dose-limiting toxicity
      (DLT) occurs in no more than 1 of 6 patients, subsequent cohorts of 6 patients each receive
      escalating doses of drug on the same schedule. Intrapatient dose escalation to the next level
      is permitted in the absence of DLT.

      PROJECTED ACCRUAL: Approximately 36 patients will be accrued for this study within 27 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1997</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven refractory solid tumor or lymphoma requiring
        systemic therapy No standard therapeutic options exist Prostate cancer patients: Tumor
        progression during blockade of testicular and adrenal androgen required PSA elevation on 2
        consecutive blood samples, 2 weeks apart Serum testosterone concentrations in the castrate
        range Leuprolide or other gonadotropin-releasing hormone (GnRH) analogs maintained if no
        prior orchiectomy No CNS neoplasms

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Platelet count at least 75,000/mm3 Absolute granulocyte count at
        least 1,000/mm3 No active coagulopathy requiring therapeutic anticoagulation Hepatic: SGOT
        and SGPT no greater than 2.5 times normal Bilirubin no greater than 1.5 times normal (3
        times normal if Gilbert's disease present) Renal: Creatinine no greater than 1.5 mg/dL OR
        Creatinine clearance at least 60 mL/min Cardiovascular: No history of unstable or newly
        diagnosed angina pectoris No myocardial infarction within past 6 months No New York Heart
        Association class II-IV heart disease Other: No serious concurrent medical illness HIV
        negative Not pregnant or nursing Negative pregnancy test Fertile patients must use
        effective contraception during and for 3 months after study

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
        since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered No prior
        flavopiridol Endocrine therapy: See Disease Characteristics A least 4 weeks since prior
        flutamide or other antiandrogen therapy without disease improvement At least 4 weeks since
        prior hormonal therapy for breast carcinoma and must show evidence of disease progression
        No concurrent corticosteroids except for physiological replacement Radiotherapy: At least 4
        weeks since prior radiotherapy and recovered At least 6 weeks since prior bone-seeking
        radioisotope therapy Surgery: Not specified Other: At least 3 months since prior suramin
        treatment At least 2 months since prior UCN-01 No concurrent anticoagulation therapy No
        other concurrent antineoplastic therapy except for GnRH for prostate cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A. Sausville, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicine Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Senderowicz AM, Messmann R, Arbuck S, et al.: A phase I trial of 1 hour infusion of flavopiridol (FLA), a novel cyclin-dependent Kinase inhibitor, in patients with advanced neoplasms. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A-796, 2000.</citation>
  </results_reference>
  <verification_date>May 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>April 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2004</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

